LOAN AGREEMENT Dated as of December 17, 2019 among GLOBAL BLOOD THERAPEUTICS, INC. (as Borrower), BIOPHARMA CREDIT PLC (as Collateral Agent and a Lender) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP (as a Lender)Loan Agreement • February 26th, 2020 • Global Blood Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, pursuant to the Loan Agreement dated as of December 17, 2019 (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”) by and among Borrower, the Collateral Agent and the other parties thereto, Lenders agrees to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein;
LICENSE AND COLLABORATION AGREEMENT by and between SYROS PHARMACEUTICALS, INC. and GLOBAL BLOOD THERAPEUTICS, INC. Dated as of December 17, 2019License and Collaboration Agreement • February 26th, 2020 • Global Blood Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is made as of December 17, 2019 (the “Effective Date”), by and between Syros Pharmaceuticals, Inc., a Delaware corporation (“Syros”), having its principal office at 35 CambridgePark Drive, Cambridge, MA 02140, and Global Blood Therapeutics, Inc., a Delaware corporation (“GBT”), having its principal office at 171 Oyster Point Blvd, Suite 300, South San Francisco, CA 94080. GBT and Syros are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
